Crack the Case #3: Antiviral Choice
Pre-Assessment

Before you view the activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit. There is no fee to participate in this activity.

Question Title

* 1. HCPs: What are your credentials?

ID MD/DO

PCP, FM, GP MD/DO

IM MD/DO

Geriatrician MD/DO

APP (NP or PA)

PharmD

Other (please specify)

Question Title

* 2. Of the following, which outpatient is at most risk for progression of COVID-19 disease?

35-year-old female smoker with irritable bowel syndrome

43-year-old male teacher with diarrhea and BMI of 27

60-year-old female marathon runner with osteoarthritis and fatigue

83-year-old indigenous male with chronic kidney disease and sore throat

Question Title

* 3. NIH treatment guidelines recommend antiviral therapy for outpatients who are at high risk for progressing to severe COVID disease in this order of preference: placeholder for Q2

MOL>PAX>RDV

RDV>PAX>MOL

PAX>RDV>MOL

PAX>MOL>RDV

Question Title

* 4. 82yoM Indigenous American w stage 3b CKD, HTN, T2DM, HLD & SARS-CoV-2+
Symptoms (for 2d): 🤒,🥱, sore throat
Rx: Atorvastatin (ATO), digoxin, losartan, dulaglutide, erythropoietin, vitamin D
Social Hx:🚫🚙, no support@ home

What do u recommend & which meds do you modify?

PAX @ ⬇️dose, 🛑ATO

RDV, no dose adjust,🛑ATO

Molnupiravir,⬇️dose,🛑ATO

Tocilizumab+admit to hosp

Question Title

* 5. For elderly immunocompromised patients taking concomitant medications requiring dose adjustments or increased monitoring, the following oral antiviral may be an option since dose adjustments are not required:

Paxlovid

Remdesivir

Molnupiravir

None of the above

Question Title

* 6. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

First Name

Last Name

Degree/Credentials

State/Province

ZIP/Postal Code

Country

Email Address (required to receive credit)

Crack the Case #3: Antiviral Choice***Pre-Assessment***

Question Title

* 1. HCPs: What are your credentials?

Question Title

* 2. Of the following, which outpatient is at most risk for progression of COVID-19 disease?

Question Title

* 3. NIH treatment guidelines recommend antiviral therapy for outpatients who are at high risk for progressing to severe COVID disease in this order of preference: placeholder for Q2

Question Title

* 4. 82yoM Indigenous American w stage 3b CKD, HTN, T2DM, HLD & SARS-CoV-2+ Symptoms (for 2d): 🤒,🥱, sore throat Rx: Atorvastatin (ATO), digoxin, losartan, dulaglutide, erythropoietin, vitamin D Social Hx:🚫🚙, no support@ home What do u recommend & which meds do you modify?

Question Title

* 5. For elderly immunocompromised patients taking concomitant medications requiring dose adjustments or increased monitoring, the following oral antiviral may be an option since dose adjustments are not required:

Question Title

* 6. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

Crack the Case #3: Antiviral Choice
Pre-Assessment

* 4. 82yoM Indigenous American w stage 3b CKD, HTN, T2DM, HLD & SARS-CoV-2+
Symptoms (for 2d): 🤒,🥱, sore throat
Rx: Atorvastatin (ATO), digoxin, losartan, dulaglutide, erythropoietin, vitamin D
Social Hx:🚫🚙, no support@ home

What do u recommend & which meds do you modify?